

\$1.2M TAX INCENTIVE TO SUPPORT GROWTH OF ZELIRA'S PORTFOLIO OF PRODUCTS

## **Key Highlights**

- Zelda receives a \$1,292,000 cash refund under the Australian Federal Government's R&D Tax Incentive Scheme.
- Funds received will be used to support Zelira's portfolio of products recently launched into global markets and to advance its ongoing clinical development programmes.

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, advises that it has received a \$1,292,000 cash refund under the Federal Government's Research and Development Tax Incentive Scheme.

The R&D Tax Incentive Scheme is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

The funds will be used to support the growth in recent launched products including Zenivol<sup>™</sup> for Insomnia, HOPE<sup>™</sup> for Autism and a new CBD-Toothpaste into global markets, and also to advance Zelira's ongoing clinical and product development programs.

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.



# For further information please contact

## Company

Dr Oludare Odumosu Managing Director & CEO \$\infty\$ +1 909 855 0675

🕏 oodumosu@zeliratx.com

#### **Investors**

Ronn Bechler Executive Chairman, Market Eye & +61 400 009 774

🛱 ronn.bechler@marketeye.com.au

## About Zelira Therapeutics

#### **Australia**

Level 3, 101 St Georges Terrace Perth WA 6000, AUSTRALIA &+61 8 6558 0886

Fax: +61 8 6316 3337

nquiries@zeliratx.com

www.zeliratx.com

ACN 103 782 378


#### **USA**

5110 Campus Drive, Suite 150 Plymouth Meeting, PA 19462 United States Of America \$\infty\$ +1 484-630-0650

### About Zelira www.zeliratx.com



Zelira Therapeutics Ltd is a leading global biopharmaceutical company manufacturing and marketing cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to access the world's largest and fastest growing markets. The Company is focused



The Company has two proprietary formulations under the HOPE™ brand that are generating revenues in Australia, Louisiana and Washington D.C. with other States in the US expected to follow.

Zelira is also generating revenue in Australia and Germany from its proprietary and patented Zenivol® - a leading cannabinoid-based medicine for treatment of chronic insomnia. Zenivol® has successfully completed the world's first cannabinoid-based efficacy trial for chronic insomnia where it was found to be a safe and effective treatment. This clinical trial was published in the prestigious peer-reviewed journal SLEEP®.

In 2020, Zelira partnered with SprinJene® Natural to develop and commercialise natural and organic oral care products under the SprinjeneCBD brand, as part of Zelira's OTC business. The SprinjeneCBD toothpaste product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids and based on the proprietary and patented technology of Blackseed oil and Zinc.

The Company has worked in partnership with world-leading researchers and organisations, which since inception include Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

